Here’s my post from January 2005, when I first bought QLTI:
QLT Phototherapeutics (QLTI) develops eye disease drugs. Down 2% since I bought it. Very high risk, but good upside potential.
I knew nothing about Visudyne, their main drug, or any of the other stuff they were developing. This was a recommendation from Motley Fool Hidden Gems, which I was experimenting with at the time as a method for finding tiny companies with growth potential.
I originally bought in 10/04 at $16 per share. Over the next year, as their shares continued to drop, I bought more at $12, and $10, and $8, and $6. I don’t know why I still liked them. Looking at their financials, their sales and cash were still going up in 2005, and I didn’t realize that their drug trials were going poorly with new drugs, and that their old Visudyne was about to be superseded by a competitor’s superior product.
Oops.
I sold a fraction of it at $9 in 2006, and bought some more at $5 in 2007. They started gushing money seriously around then, and I stopped being interested. Their stock recently bounced back over $5/share, so I dumped the rest of it. Their financials look less miserable than they did over the last couple of years, but still seem poor. I’m glad to be rid of this embarrassment.
Over the years, I piled $8336 into this company, and took $4109 out, losing more than half. Could be worse, I guess, especially for a stock I categorized as “very high risk” when I bought it. My memory is fuzzy, but I’m guessing the upside potential was if their new drugs had panned out. They didn’t. If they had, it’s easy to imagine that this might have been highly profitable.
The worst thing is that this so-called investment was in Mary’s IRA account, so I blew her retirement money. And there’s not even any tax benefit for the loss. Poo.